Vericel (NASDAQ:VCEL – Get Rating) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Profitability

This table compares Vericel and Allena Pharmaceuticals' net margins, return on equity and return on assets.

Get Vericel alerts:

Risk and Volatility

Vericel has a beta of 1.99, suggesting that its stock price is 99% more volatile than the S&P 500. Comparatively, Allena Pharmaceuticals has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Institutional & Insider Ownership

7.3% of Allena Pharmaceuticals shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 3.7% of Allena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Vericel and Allena Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Vericel has higher revenue and earnings than Allena Pharmaceuticals.

Analyst Ratings

This is a summary of recent recommendations and price targets for Vericel and Allena Pharmaceuticals, as provided by MarketBeat.

Vericel presently has a consensus price target of $37.40, suggesting a potential upside of 57.14%. Given Vericel's higher possible upside, equities research analysts clearly believe Vericel is more favorable than Allena Pharmaceuticals.

Summary

Vericel beats Allena Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

About Vericel

(Get Rating)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

About Allena Pharmaceuticals

(Get Rating)

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.